Myeloma Minute: Physical Distancing Continues


| INNOVATION | Latest Research


COVID-19 Update: Truth, Testing, and The Future

New COVID-19 studies suggest that in order to suppress the infection, we will need to follow physical distancing guidelines longer than we thought. Dr. Brian G.M. Durie explains how this and other news reports can help us live safely in a pandemic, and still manage to have some fun.


| EDUCATION | Webinar


Watch a Replay of This Patient & Family Webinar

Watch a replay of this past weekend’s IMF Patient & Family Webinar. This two-hour webinar features a panel discussion about the latest treatments for and management of myeloma led by IMF Chairman Dr. Brian G.M. Durie. Panelists include Dr. Joseph Mikhael of the Translational Genomics Research Institute (TGen), Dr. William Bensinger of the Swedish Medical Center, and Joseph Tariman PhD, RN, from the School of Nursing/College of Science and Health at DePaul University. The IMF is grateful to our sponsors who have who provided virtual resource tables here.


| INSPIRATION | Vacation Getaway


| EDUCATION | Myeloma Today


And This Too Shall Pass….
Hot Off the Press: Spring 2020 Edition of Myeloma Today

Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself sipping a tropical beverage next to a private pool, just minutes from the Hawaiian coastline.

The Spring 2020 edition of Myeloma Today is now available as a free download or printed copy. Read about current immunotherapy approaches that are attacking myeloma cells in new ways, the role of Sarclisa® (isatuximab) in relapsed refractory disease, and more. Medical articles are translated and available in French, Italian, German, and Spanish.





Tune in to the New “A Day in the Life” Podcast, Spotlighting Myeloma Patients

The new “A Day in the Life” podcast from the IMF features messages of hope and resilience for myeloma patients, caregivers, and their loved ones. Tune in to this interview with Mark Ho, a myeloma patient whose life’s journey has gone from serving as a U.S. Marine to counseling fellow veterans. Today, he performs hip hop under the stage name Bag-Yo.


| ACTION | Food Assistance


COVID-19 Food Assistance Program

In need of assistance for grocery bills during the pandemic? Learn about this program that “supports patients with cancer, multiple sclerosis or rheumatoid arthritis who are unable to afford or access food or nutritional needs due to COVID-19. This program is made possible with support by Bristol-Myers Squibb.


| INNOVATION | Clinical Trial


Sarclisa (isatuximab) Phase 3 Trial Meets Primary Endpoint

On May 12, 2020, the “the phase III IKEMA clinical trial evaluating Sarclisa® (isatuximab) added to carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis, demonstrating significantly prolonged progression-free survival compared to standard of care carfilzomib and dexamethasone alone in patients with relapsed multiple myeloma.”


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Myeloma and Coronavirus
IMF "Living Well with Myeloma"
Webinar Replay

Deadline: August 1, 2020
Brian D. Novis Research Grant
Apply Today

Hawaiian Vacation Raffle
Kailua-Kona, Hawaii

Hatfield Hike
Appalachian Trail

subscribe_button.png     donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, GSK, Sanofi-Genzyme, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.